You are here

MEMS Reagentless Biosensor

Award Information
Agency: Department of Defense
Branch: Army
Contract: N/A
Agency Tracking Number: 36901
Amount: $749,942.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1998
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
401 Camp Craft Rd
Austin, TX 78746
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dr. Robert C. Chin
 (512) 306-1100
Business Contact
Phone: () -
Research Institution

One of the most serious obstacles to the practical implementation of biosensor technology for BW and CW detection onto UAV 5 and other remote deployment applications is the need for miniaturization of the sensor systems. To meet this need, Systems & Processes Engineering Corporation (SPEC) proposes to develop a miniaturized biosensor system which is essentially reagentless. The proposed system will use a novel fluorescence quenching strategy with no antibody separation steps or sophisticated multiple-fluid injection steps. The proposed system will be implemented into a MEM package which will include a telemetry system for remote deployment applications. The MEM package will include submodules for electronics, microfluidics, optics and air intake and sample preparation and will be designed to be less than 2"x2"x1" in size. The proposed antibody engineering for a fluorescence quenching immunoassay, will be done using novel mutagenesis and antibody expression methods recently developed by Drs. Iverson and Georgiou's. To implement the proposed fluorescence quenching immunoassay into a MEMS, SPEC has developed a teaming arrangement with the MEMS foundry at MCNC. The proposed microfluidic design will be developed by SPEC and MCNC design tool technology will be used to implement the micro-biosensor design in Phase II. The development of the fluorescence quenching immunoassay will provide a technology for clinical applications which is reagentless. The MEM biosensor system permits the developrnent of small, highly portable diagnostic systems. The use of Drs. Iverson and Georgiou's patented process for systematic optimization of antibody affinity by saturation mutagenesis will allow the development of high specificity, high affinity antibodies where none currently exist. These technologies, both in combination and individually have significant use in warfare, environmental, agricultural and medical applications.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government